Shopping Cart
Remove All
Your shopping cart is currently empty
TargetMol Star Molecule—Paclitaxel (Cat. No. T0968, CAS 33069-62-4), Exploring the Crosstalk Between Microtubule Dynamics, Apoptosis, and Autophagy
Background
Molecular Structure of Paclitaxel
Paclitaxel (T0968) is a naturally derived microtubule polymer stabilizer that exerts its biological effects primarily through modulation of the microtubule cytoskeleton. By binding to β-tubulin subunits within microtubules, Paclitaxel promotes and stabilizes microtubule polymerization, preventing their normal dynamic disassembly during mitosis. This stabilization disrupts the mitotic spindle apparatus, leading to mitotic arrest and activation of downstream signaling pathways that culminate in programmed cell death, including apoptosis and autophagy. The compound’s interaction with microtubules thus directly influences key cellular processes involved in cell cycle progression and survival. In the context of apoptosis, Paclitaxel-induced mitotic arrest triggers intrinsic apoptotic pathways characterized by mitochondrial outer membrane permeabilization and caspase activation. Concurrently, Paclitaxel can induce autophagic responses, which may serve as a cellular attempt to mitigate stress or alternatively contribute to cell death, highlighting its multifaceted role in modulating cell fate. Additionally, Paclitaxel has been utilized as an antibody-drug conjugate (ADC) cytotoxin, leveraging its cytotoxic properties to selectively target cells expressing specific surface antigens, thereby enhancing its utility in targeted research applications. In experimental settings, Paclitaxel is widely employed to investigate microtubule dynamics, mitotic checkpoint mechanisms, and the interplay between apoptosis and autophagy pathways. Its ability to induce mitotic arrest and subsequent cell death pathways makes it a valuable tool for dissecting the molecular underpinnings of cell cycle regulation and programmed cell death. Furthermore, Paclitaxel’s role in modulating ADC cytotoxin pathways provides a platform for studying targeted delivery systems and cytotoxic payload effects in cancer biology research. Overall, Paclitaxel (T0968) serves as a critical biochemical probe for elucidating microtubule-associated processes and the complex signaling networks governing apoptosis and autophagy, with broad implications for understanding cellular homeostasis and stress responses in diverse biological contexts [1,2].
Literature review
2.1 Allopregnanolone relieves paclitaxel induced mechanical hypersensitivity via inhibiting spinal cord PGE2-EP2 mediated microglia-neuron signaling
Paclitaxel(T0968) induces chemotherapy-induced neuropathic pain characterized by mechanical hypersensitivity in rats. The study demonstrates that Paclitaxel treatment causes upregulation of microglial activation markers, including Iba-1 and phosphorylated ERK (p-ERK), within the dorsal spinal cord. Furthermore, Paclitaxel increases the expression of pro-inflammatory mediators PGE2 and its receptor EP2. These neuroinflammatory changes correlate with heightened mechanical hypersensitivity observed in the model. Additionally, Paclitaxel reduces the endogenous level of allopregnanolone, a neurosteroid, in the dorsal spinal cord. Interventions targeting microglial p-ERK activity can inhibit these markers and partially alleviate mechanical hypersensitivity, highlighting the role of Paclitaxel-induced microglial activation and neuroinflammation in producing neuropathic pain.[3]
2.2 VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination
Paclitaxel(T0968) was studied in vivo in a lung squamous cell carcinoma model where it was administered intraperitoneally at 10 mg/kg three alternate days weekly. The findings demonstrated that blocking the tubulin carboxypeptidase activity of VASH2 enhanced the treatment efficacy of paclitaxel by inhibiting xenograft tumor growth. Tumor volume and body weight were monitored regularly to evaluate the drug's impact. These results indicate that paclitaxel effectiveness can be improved in the presence of VASH2 inhibition, suggesting an enhancement effect by paclitaxel on tumor suppression when combined with modulation of tubulin detyrosination pathways.[4]
2.3 Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling
Paclitaxel(T0968) exhibited effects on endometrial cancer (EC) cell viability as shown in the experiments evaluating drug impacts on EC cells. The study demonstrated that MYH14, a myosin family member, impaired cell sensitivity to paclitaxel, indicating a role in chemoresistance within EC. This chemoresistance was identified as a mechanism by which EC cells evade the cytotoxic effects of paclitaxel. Further investigation revealed that co-administration of paclitaxel with sesamolin, an MYH14 inhibitor, produced a synergistic effect, enhancing the responsiveness of EC cells to chemotherapy. This suggests that combining paclitaxel with agents targeting MYH14 could improve chemosensitivity and overcome resistance in EC. Overall, the presence of MYH14 reduced the efficacy of paclitaxel by promoting resistance, while its inhibition by sesamolin sensitized EC cells to this drug, highlighting resistance as the main effect of paclitaxel observed in this study.[5]
2.4 A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma
Paclitaxel(T0968), as part of the Gem-Pac combination, was evaluated for its effect on metastatic pancreatic ductal adenocarcinoma (PDAC) using patient serum-derived educated spheroids. In this study, a personalized chemogram platform assessed the responses of four metastatic PDAC patients to gemcitabine monotherapy, Gem-Pac, and FOLFIRINOX regimens. Two patients demonstrated sensitivity to both gemcitabine and the Gem-Pac combination, though no additional advantage was observed from the inclusion of paclitaxel within Gem-Pac. Conversely, a third patient responded only to gemcitabine monotherapy and showed no sensitivity to Gem-Pac, indicating variable responses to paclitaxel-containing combination therapy at the cellular level. These differential responses likely reflect heterogeneous tumor cell treatment tolerance and resistance mechanisms in patients. Overall, paclitaxel within the combination influenced drug sensitivity variably among individuals, supporting its evaluation through a personalized chemogram to refine optimal therapeutic protocols.[6]
2.5 MAP4 phosphorylation induced by ARID1A loss sensitizes colorectal cancer cells to EMP
Paclitaxel(T0968), represented in this study by its alias estramustine phosphate sodium (EMP), functions as an antimicrotubule agent that binds to microtubule-associated proteins and induces microtubule depolymerization, causing G2/M cell cycle arrest and apoptosis. In colorectal cancer cell lines with ARID1A loss, EMP exhibited a synthetic lethal effect, demonstrated by significantly lower IC50 values compared to ARID1A wild-type cells, showing approximately 2-fold increased sensitivity. EMP treatment selectively inhibited cell viability and induced apoptosis in ARID1A-deficient cells, and it also significantly reduced clonogenic survival. These experimental results indicate that Paclitaxel(T0968) effectively suppresses proliferation and survival of colorectal cancer cells harboring ARID1A loss by disrupting microtubule dynamics and inducing mitotic cell death. The data confirm that Paclitaxel(T0968) exerts selective inhibitory effects in the context of ARID1A deficiency, underlining its role in limiting cancer cell viability and clonogenic potential in this genetic background.[7]
Reference
[1] 1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665-7.
[2] 2. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-65.
[3] Guo K, Gao L, Li P, Feng S, Zhao L, Wang X. Allopregnanolone relieves paclitaxel induced mechanical hypersensitivity via inhibiting spinal cord PGE2-EP2 mediated microglia-neuron signaling. IBRO Neuroscience Reports. 2025;18():211-221.
[4] Wang J, Liu P, Zhang R, Xing B, Chen G, Han L, et al.. VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination. Cell Death & Disease. 2024;15(10):.
[5] Lin Y, Chen X, Lin L, Xu B, Zhu X, Lin X. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling. Cellular & Molecular Biology Letters. 2024;29(1):.
[6] Cherradi S, Roux S, Dupuy M, Assenat E, Duong H. A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma. Translational Oncology. 2026;64():102659.
[7] Pan L, Wu D, He Y, Wang K, Zeng Y, Xiang C, et al.. MAP4 phosphorylation induced by ARID1A loss sensitizes colorectal cancer cells to EMP. Cell Death & Disease. 2025;17(1):.
Other Articles
Subscription to TargetMol News
An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.